Related Experiment Video

Updated: May 24, 2026

Development and Application of Rapamycin-regulated Tyrosine Phosphatases
06:56

Development and Application of Rapamycin-regulated Tyrosine Phosphatases

Published on: September 6, 2024

Potential therapeutic applications of phosphodiesterase inhibition in prostate cancer

Thomas K Hamilton1, Nianping Hu, Klodiana Kolomitro

  • 1Department of Anatomy and Cell Biology, Queen's University, Kingston, ON, Canada.

World Journal of Urology
|March 3, 2012
PubMed
Abstract

Insights

Phosphodiesterase (PDE) inhibitors combat hypoxia-induced chemoresistance and immune escape in prostate cancer. Targeting PDE5 and PDE11 shows promise for enhancing cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Cyclic guanosine monophosphate (cGMP) signaling influences cancer progression.
  • cGMP signaling is implicated in protecting against hypoxia-induced cancer progression.
  • The role of PDEs in chemoresistance and immune escape under hypoxia is not fully understood.

Purpose of the Study:

  • To investigate the role of phosphodiesterases (PDEs) in hypoxia-mediated chemoresistance in prostate cancer.
  • To determine the effect of PDE inhibition on immune escape mechanisms in prostate cancer.
  • To evaluate the therapeutic potential of PDE inhibitors in prostate cancer treatment.

Main Methods:

  • PDE activity was measured in prostate cancer cell lines (DU145, PC3).
  • PDE expression was confirmed in human prostate tissue via immunoblots.
  • Chemoresistance, MICA shedding, and in vivo tumor growth were assessed following PDE inhibition under hypoxic conditions.

Main Results:

  • PDE5 and PDE11 were the predominant PDEs, accounting for 86-95% of cGMP-specific activity.
  • PDE inhibition significantly reduced doxorubicin resistance by 51% in DU-145 cells under hypoxia.
  • PDE inhibition reversed hypoxia-induced MICA shedding and attenuated tumor xenograft growth in mice.

Conclusions:

  • PDE inhibitors demonstrate potential in overcoming hypoxia-induced chemoresistance in prostate cancer.
  • Targeting PDEs may enhance anti-tumor immunity by modulating MICA expression.
  • These findings support further investigation of PDE inhibitors as a therapeutic strategy for prostate cancer.

More Related Videos

Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer12:23

Phosphopeptide Enrichment Coupled with Label-free Quantitative Mass Spectrometry to Investigate the Phosphoproteome in Prostate Cancer

Published on: August 2, 2018

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy09:49

Isolation of Adipose Derived Regenerative Cells for the Treatment of Erectile Dysfunction Following Radical Prostatectomy

Published on: December 28, 2021

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...